Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis

Miltefosine (42 Days) for Mucosal Leishmaniasisi

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00373568

Enrollment

Registered

2006-09-08

Start date

2005-04-30

Completion date

2007-12-31

Last updated

2010-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leishmaniasis

Keywords

mucosal, miltefosine

Brief summary

Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis

Detailed description

Miltefosine (42 days) will be used to try to improve upon the cure rate with 28 days of drug for bolivian mucosal leishmaniasisi

Interventions

DRUGmiltefosine: 2.5 mg/kg/day for 42 days

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Mucosal leishmaniasis

Exclusion criteria

* No comcomitant disease as judged by laboratory and clinical parameters

Design outcomes

Primary

Measure	Time frame
efficacy	—

Secondary

Measure	Time frame
safety	—

Countries

Bolivia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026